<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558465</url>
  </required_header>
  <id_info>
    <org_study_id>17522</org_study_id>
    <secondary_id>XAR-PE-DVT</secondary_id>
    <nct_id>NCT02558465</nct_id>
  </id_info>
  <brief_title>Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)</brief_title>
  <acronym>JPMS-XAR-VTE</acronym>
  <official_title>Special Drug Use Investigation of Xarelto for VTE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to assess safety and effectiveness of Xarelto under
      practice routine use in VTE secondary prevention after acute DVT, focusing on
      hemorrhagic-related AEs, recurrent venous thromboembolism (PE/DVT), all-cause mortality. This
      study is a company sponsored, one- arm prospective cohort study with patients to whom
      Rivaroxaban treatment for VTE (PE/DVT) has been chosen. The study includes a standard
      observation period (1 year) and an extension survey period (2 years, at the longest).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2015</start_date>
  <completion_date type="Anticipated">January 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with ISTH (International Society on Thrombosis and Haemostasis) major bleeding as a measure of Safety and tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with symptomatic recurrent VTE (composite of DVT or nonfatal or fatal pulmonary embolism)</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite number of all-cause mortality, vascular events (acute coronary syndrome, ischemic stroke, transient ischemic attack, or systemic embolism), clinically relevant non-major bleeding and all other adverse events/ADRs</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with asymptomatic deterioration of thrombotic burden (change of D-dimer, imaging test such as CT or CCUS) by the end of standard observation period</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of VTE recurrence and adverse events/ADRs comparison between distal and/or proximal DVT localization treatment outcomes</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1250</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
    <description>Rivaroxavban administration group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>Treatment parameters following the summary of product characteristics and the physician's decision</description>
    <arm_group_label>Rivaroxaban (Xarelto, BAY59-7939)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female and male patients who start rivaroxaban for VTE ï¼ˆpulmonary embolism, deep vein
        thrombosis) anticoagulation therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who start rivaroxaban for VTE(pulmonary embolism, deep vein thrombosis)
             anticoagulation therapy

        Exclusion Criteria:

          -  Patients who are contraindicated based on the product label and have already received
             Xarelto treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+) 1-888-8422937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Many locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xarelto, rivaroxaban, VTE, PE, DVT, Japan, PMS, SDUI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

